Terms: = Prostate cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
35 results:
1. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide.
Podgoršek E; Mehra N; van Oort IM; Somford DM; Boerrigter E; van Erp NP
Clin Pharmacokinet; 2023 Aug; 62(8):1049-1061. PubMed ID: 37458966
[TBL] [Abstract] [Full Text] [Related]
2. Cold atmospheric plasma enhances doxorubicin selectivity in metastasic bone cancer.
Mateu-Sanz M; Ginebra MP; Tornín J; Canal C
Free Radic Biol Med; 2022 Aug; 189():32-41. PubMed ID: 35843475
[TBL] [Abstract] [Full Text] [Related]
3. Effect of enzalutamide on PK of P-gp and bcrp substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract] [Full Text] [Related]
4. Possibility of paclitaxel to induce the stemness-related characteristics of prostate cancer cells.
Içduygu FM; Samli H; Özgöz A; Vatansever B; Oztürk KH; Akgün E
Adv Clin Exp Med; 2021 Dec; 30(12):1283-1291. PubMed ID: 34610216
[TBL] [Abstract] [Full Text] [Related]
5. Predictors of therapeutic efficacy of 5-aminolevulinic acid-based photodynamic therapy in human prostate cancer.
Yamamoto S; Fukuhara H; Seki H; Kawada C; Nakayama T; Karashima T; Ogura SI; Inoue K
Photodiagnosis Photodyn Ther; 2021 Sep; 35():102452. PubMed ID: 34303032
[TBL] [Abstract] [Full Text] [Related]
6. Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells.
Uwada J; Mukai S; Terada N; Nakazawa H; Islam MS; Nagai T; Fujii M; Yamasaki K; Taniguchi T; Kamoto T; Yazawa T
Life Sci; 2021 Aug; 278():119554. PubMed ID: 33932444
[TBL] [Abstract] [Full Text] [Related]
7. The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression.
Sauer H; Kampmann H; Khosravi F; Sharifpanah F; Wartenberg M
Clin Exp Pharmacol Physiol; 2021 Mar; 48(3):422-434. PubMed ID: 33349973
[TBL] [Abstract] [Full Text] [Related]
8. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract] [Full Text] [Related]
9. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(5):460-467. PubMed ID: 30880686
[TBL] [Abstract] [Full Text] [Related]
10. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract] [Full Text] [Related]
11. Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway.
Erdogan S; Turkekul K; Dibirdik I; Doganlar O; Doganlar ZB; Bilir A; Oktem G
Biomed Pharmacother; 2018 Nov; 107():793-805. PubMed ID: 30142541
[TBL] [Abstract] [Full Text] [Related]
12. DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop.
Vella V; Nicolosi ML; Cantafio P; Massimino M; Lappano R; Vigneri P; Ciuni R; Gangemi P; Morrione A; Malaguarnera R; Belfiore A
Endocr Relat Cancer; 2019 Jan; 26(1):197-214. PubMed ID: 30121624
[TBL] [Abstract] [Full Text] [Related]
13. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in prostate cancer Cells.
Liu H; Song X; Hou J; Zhao Z; Chang J
DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
[TBL] [Abstract] [Full Text] [Related]
14. Contrasting roles of the abcg2 Q141K variant in prostate cancer.
Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
[TBL] [Abstract] [Full Text] [Related]
15. ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.
Yu D; Zhong Y; Li X; Li Y; Li X; Cao J; Fan H; Yuan Y; Ji Z; Qiao B; Wen JG; Zhang M; Kvalheim G; Nesland JM; Suo Z
Oncotarget; 2015 Dec; 6(40):42687-703. PubMed ID: 26528857
[TBL] [Abstract] [Full Text] [Related]
16. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract] [Full Text] [Related]
17. Insights into Chemoresistance of prostate cancer.
Zhang W; Meng Y; Liu N; Wen XF; Yang T
Int J Biol Sci; 2015; 11(10):1160-70. PubMed ID: 26327810
[TBL] [Abstract] [Full Text] [Related]
18. Androgen Receptor Targeted Conjugate for Bimodal Photodynamic Therapy of prostate cancer in Vitro.
Rapozzi V; Ragno D; Guerrini A; Ferroni C; della Pietra E; Cesselli D; Castoria G; Di Donato M; Saracino E; Benfenati V; Varchi G
Bioconjug Chem; 2015 Aug; 26(8):1662-71. PubMed ID: 26108715
[TBL] [Abstract] [Full Text] [Related]
19. Functional cyclic AMP response element in the breast cancer resistance protein (bcrp/abcg2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated bcrp/abcg2 transcription in human cancer cells.
Xie Y; Nakanishi T; Natarajan K; Safren L; Hamburger AW; Hussain A; Ross DD
Biochim Biophys Acta; 2015 Mar; 1849(3):317-27. PubMed ID: 25615818
[TBL] [Abstract] [Full Text] [Related]
20. PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer.
Kim RJ; Bae E; Hong YK; Hong JY; Kim NK; Ahn HJ; Oh JJ; Park DS
Oncology; 2014; 87(5):270-9. PubMed ID: 25139413
[TBL] [Abstract] [Full Text] [Related]
[Next]
